GLP-1 receptor agonists raise risk of biliary disease: review

The findings point to 'potential under-reporting' of biliary-related adverse events, researchers say

GLP-1 receptor agonists raise the risk of gall bladder and bile duct diseases, especially when prescribed at higher doses for weight loss, according to a systematic review and meta-analysis.

Although the absolute risk increase was modest, Chinese researchers say doctors and patients should still be alert to these safety signals both in clinical practice and future trials.

Dr Huabing Zhang and colleagues from the Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing reviewed 76 randomised